Industry
Biotechnology
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 8:18 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:58 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 11:36 am
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 12:29 pm
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
July 15, 2024 | 8:13 pm
Portfolio Pulse from Benzinga Newsdesk
July 15, 2024 | 11:38 am
Portfolio Pulse from Benzinga Newsdesk
July 15, 2024 | 11:09 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.